FDA
label_change
· 2021-01-30
FDA Approved: UPTRAVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
Summary
FDA approved a supplemental application for Uptravi (selexipag) to update the labeling; Uptravi is used for pulmonary arterial hypertension and is manufactured …
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for UPTRAVI (SELEXIPAG)